EGFR tyrosine kinase inhibitors (TKIs) represent the recommended first-line treatment in patients with advanced NSCLC and common mutations, i.e. exon 19 deletions (Ex19dels) and exon 21 point mutation (L858R). Here, EGFR is linked to non-small cell lung carcinoma.